A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.

Abstract Our previous randomized phase 3 trial showed that S-1 as a first-line chemotherapy for metastatic breast cancer is non-inferior to taxane with respect to overall survival. In this study, we investigated the usefulness of matabolism-related genes as predictive biomarkers of treatment response to S-1 from the previous trial. We found no association between metabolic-related genes and treatment response to S-1.